The Mφ deactivator semapimod inhibited the secretion of HMGB1 and reduced the expression of its receptor for advanced glycation end products (RAGE), thereby reducing intestinal cell death and inflammatory response in a rat model of NEC (134). Here, HMGB1 is linked to necrotizing enterocolitis.